Analytical Data
-
Gene name
ETV5
- Application
-
Alternative Names
ERM; Ets-Related Molecule; ETS translocation variant 5
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41161
-
Expression Region
Ser242~Tyr510
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ETV5, a member of the Ets transcription factor family, has garnered significant attention in recent years due to its role in various biological processes and its implications in cancer. Initially studied for its involvement in developmental processes, ETV5 has been identified as a key player in cell proliferation, differentiation, and survival. Importantly, the dysregulation of ETV5 expression has been linked to several malignancies, including prostate cancer, where it acts as an oncogenic driver. Researchers are increasingly focused on understanding the molecular mechanisms by which ETV5 influences gene expression and cell behavior, as this knowledge may reveal potential therapeutic targets. The recombinant production of ETV5 protein has enabled detailed structural and functional studies, shedding light on its interaction with DNA and other proteins, and facilitating the development of inhibitors targeting ETV5's activity. As cancer research progresses, the study of ETV5 continues to unveil its dual role in normal physiology and pathogenesis, highlighting its potential as a biomarker and a strategic target for cancer treatment.
